11/7
08:07 am
abcl
AbCellera Biologics (NASDAQ:ABCL) had its "market perform" rating reaffirmed by analysts at Leerink Partners. They now have a $4.00 price target on the stock.
Medium
Report
AbCellera Biologics (NASDAQ:ABCL) had its "market perform" rating reaffirmed by analysts at Leerink Partners. They now have a $4.00 price target on the stock.
11/7
07:20 am
abcl
Rating for ABCL
Low
Report
Rating for ABCL
11/7
06:12 am
abcl
AbCellera downgraded to Market Perform from Outperform at Leerink
Medium
Report
AbCellera downgraded to Market Perform from Outperform at Leerink